Compare Gilead Sciences, Inc. (GILD) vs Iris Energy Limited (IREN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Iris Energy Limited — how do they compare? Gilead Sciences, Inc. trades at $135.67 (market cap $163.51B), while Iris Energy Limited trades at $35.42 (market cap $13.68B). The key difference: Gilead Sciences, Inc. is far larger — about 12× Iris Energy Limited's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| GILD | IREN | |
|---|---|---|
Market Cap | $163.51B | $13.68B |
Sector | Health | Energy |
52-Week High | $155.80 | $76.41 |
52-Week Low | $108.22 | $15.40 |
Enterprise Value | $178.05B | $15.43B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
IREN is trading at $34.77, down 9.9% in the last 24 hours amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth projections ($757M for 2026) but recent earnings misses and negative ROE/ROA. Analyst sentiment remains predominantly bullish with a $79.11 consensus price target, though technical indicators suggest near-term pressure with support at $35.
The outlook hinges on IREN's transformation from Bitcoin mining to AI infrastructure execution. While contracted ARR targets and AI cloud growth present upside, risks include competitive threats from Meta's cloud plans and recent governance concerns. Current valuation multiples appear elevated relative to profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
